Premium
Survival in HIV‐infected patients is associated with hepatitis C virus infection and injecting drug use since the use of highly active antiretroviral therapy in the Lyon observational database
Author(s) -
Voirin N.,
Trépo C.,
Miailhes P.,
Touraine J. L.,
Chidiac C.,
Peyramond D.,
Livrozet J. M.,
Ritter J.,
Chevallier P.,
Fabry J.,
Allard R.,
Vanhems P.
Publication year - 2004
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/j.1365-2893.2004.00544.x
Subject(s) - antiretroviral therapy , observational study , medicine , human immunodeficiency virus (hiv) , virology , hepatitis c virus , drug , viral load , virus , pharmacology
Summary. Highly active antiretroviral therapy (HAART) has reduced the incidence of death in HIV‐infected patients but various rates of survival have been reported due to the infection with hepatitis C virus (HCV) and the use of injecting drugs (IDU). A survival analysis was performed to estimate and compare the death rates in HIV‐positive patients infected by IDU and/or positive for HCV antibodies in the pre‐HAART and HAART periods in Lyon (France) between 1992 and 2002. Patients were stratified into four groups (G): HCV−/IDU−(G1), HCV+/IDU−(G2), HCV+/IDU−(G3), HCV+/IDU+ (G4) and adjusted death rates in the pre‐HAART era (< 1996) and the HAART era (≥ 1996) were compared. The aHR of progression to death was 1.05 (95% CI 0.75–1.47, P = 0.75) for G2, 1.09 (95% CI 0.54–2.22, P = 0.81) for G3 and 0.90 (95% CI 0.65–1.24, P =0.51) for G4 compared with G1 in the pre‐HAART era. The aHR of progression to death was 0.76 (95% CI 0.28–2.08, P = 0.59) for G2, 1.23 (95% CI 0.17–8.86, P = 0.84) for G3 and 2.90 (95% CI 1.62–5.20, P < 0.001) for G4, compared with G1 in the HAART era. HAART management of HCV+/IDU+ patients needs to be optimized for them to achieve a similar benefit as observed among other individuals.